usp2 catalytic domain Search Results


94
R&D Systems e 322 human usp2 catalytic domain r d systems
E 322 Human Usp2 Catalytic Domain R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/e 322 human usp2 catalytic domain r d systems/product/R&D Systems
Average 94 stars, based on 1 article reviews
e 322 human usp2 catalytic domain r d systems - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

91
Boston Biochem human usp2 catalytic domain protein
Cell lysates were prepared from MCF7 cells maintained at 37°C or heat‐shocked at 42°C for 1 h. Where indicated, lysate from heat‐shocked cells was incubated with recombinant <t>USP2</t> to remove polyubiquitin chains. Equal amounts of cell lysate were assayed for the levels of the indicated proteins by immunoblotting. A quantification of the levels of K48‐linked polyubiquitin is shown in the bar graph (means ± SD, n = 4, number indicates P value calculated with the two‐stage linear step‐up procedure of Benjamini, Krieger, and Yekutieli). Equal amounts of cell lysate described in (A) were fractionated by sucrose density gradient centrifugation, and K48‐linked polyubiquitin was detected by immunoblotting. Quantification of K48‐linked polyubiquitin across the gradients relative to the levels obtained in MCF7 cells maintained at 37°C (means ± SEM, n = 3). Trypsin‐like proteasome activity determined in the same fractions as in (B). Results are shown relative to the proteasome activity obtained in MCF7 cells maintained at 37°C (means ± SEM, n = 3). Source data are available online for this figure.
Human Usp2 Catalytic Domain Protein, supplied by Boston Biochem, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human usp2 catalytic domain protein/product/Boston Biochem
Average 91 stars, based on 1 article reviews
human usp2 catalytic domain protein - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier

94
R&D Systems recombinant usp2 catalytic domain
Cell lysates were prepared from MCF7 cells maintained at 37°C or heat‐shocked at 42°C for 1 h. Where indicated, lysate from heat‐shocked cells was incubated with recombinant <t>USP2</t> to remove polyubiquitin chains. Equal amounts of cell lysate were assayed for the levels of the indicated proteins by immunoblotting. A quantification of the levels of K48‐linked polyubiquitin is shown in the bar graph (means ± SD, n = 4, number indicates P value calculated with the two‐stage linear step‐up procedure of Benjamini, Krieger, and Yekutieli). Equal amounts of cell lysate described in (A) were fractionated by sucrose density gradient centrifugation, and K48‐linked polyubiquitin was detected by immunoblotting. Quantification of K48‐linked polyubiquitin across the gradients relative to the levels obtained in MCF7 cells maintained at 37°C (means ± SEM, n = 3). Trypsin‐like proteasome activity determined in the same fractions as in (B). Results are shown relative to the proteasome activity obtained in MCF7 cells maintained at 37°C (means ± SEM, n = 3). Source data are available online for this figure.
Recombinant Usp2 Catalytic Domain, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant usp2 catalytic domain/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant usp2 catalytic domain - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

93
Boston Biochem deubiquitinase usp2
Cell lysates were prepared from MCF7 cells maintained at 37°C or heat‐shocked at 42°C for 1 h. Where indicated, lysate from heat‐shocked cells was incubated with recombinant <t>USP2</t> to remove polyubiquitin chains. Equal amounts of cell lysate were assayed for the levels of the indicated proteins by immunoblotting. A quantification of the levels of K48‐linked polyubiquitin is shown in the bar graph (means ± SD, n = 4, number indicates P value calculated with the two‐stage linear step‐up procedure of Benjamini, Krieger, and Yekutieli). Equal amounts of cell lysate described in (A) were fractionated by sucrose density gradient centrifugation, and K48‐linked polyubiquitin was detected by immunoblotting. Quantification of K48‐linked polyubiquitin across the gradients relative to the levels obtained in MCF7 cells maintained at 37°C (means ± SEM, n = 3). Trypsin‐like proteasome activity determined in the same fractions as in (B). Results are shown relative to the proteasome activity obtained in MCF7 cells maintained at 37°C (means ± SEM, n = 3). Source data are available online for this figure.
Deubiquitinase Usp2, supplied by Boston Biochem, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/deubiquitinase usp2/product/Boston Biochem
Average 93 stars, based on 1 article reviews
deubiquitinase usp2 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

90
Boston Biochem catalytic domain of usp2 e-506
(a) Schematic illustration of human Cdc20. Asterisks indicate lysine residues. (b) Ubiquitination/dissociation of Cdc20 requires lysines in the N-terminal region. In vitro ubiquitination assays were performed with APC re-loaded with double HA-tagged human WT or Cdc20 mutants as described in . (c) Deubiquitination of ubiquitinated Cdc20 increases its affinity for the APC. Supernatant from an in vitro Cdc20 ubiquitination assay containing ubiquitinated Cdc20 was divided into two aliquots and one aliquot was incubated with the catalytic domain of <t>Usp2</t> (Usp2-CD). Both aliquots were then re-incubated with a fresh batch of high salt-washed APC to assess the binding of Cdc20. (d) Unmodified Cdc20 outcompetes ubiquitinated Cdc20 for binding to the APC. Ubiquitinated Cdc20 (Ub-Cdc20) was generated as in (c) and mixed with reticulocyte lysate containing unmodified Cdc20 at different ratios. The mixture was then incubated with high salt-washed APC and Cdc20 binding was assessed by Western blot. (e) Cdc20 1-164R is more resistant to TAME-induced dissociation than WT Cdc20. APC beads loaded with WT or Cdc20 1-164R were incubated in mitotic extract +/- TAME for 10 min. A fraction of the beads were then treated with Usp2-CD.
Catalytic Domain Of Usp2 E 506, supplied by Boston Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/catalytic domain of usp2 e-506/product/Boston Biochem
Average 90 stars, based on 1 article reviews
catalytic domain of usp2 e-506 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Enzo Biochem usp2 catalytic domain
(a) Schematic illustration of human Cdc20. Asterisks indicate lysine residues. (b) Ubiquitination/dissociation of Cdc20 requires lysines in the N-terminal region. In vitro ubiquitination assays were performed with APC re-loaded with double HA-tagged human WT or Cdc20 mutants as described in . (c) Deubiquitination of ubiquitinated Cdc20 increases its affinity for the APC. Supernatant from an in vitro Cdc20 ubiquitination assay containing ubiquitinated Cdc20 was divided into two aliquots and one aliquot was incubated with the catalytic domain of <t>Usp2</t> (Usp2-CD). Both aliquots were then re-incubated with a fresh batch of high salt-washed APC to assess the binding of Cdc20. (d) Unmodified Cdc20 outcompetes ubiquitinated Cdc20 for binding to the APC. Ubiquitinated Cdc20 (Ub-Cdc20) was generated as in (c) and mixed with reticulocyte lysate containing unmodified Cdc20 at different ratios. The mixture was then incubated with high salt-washed APC and Cdc20 binding was assessed by Western blot. (e) Cdc20 1-164R is more resistant to TAME-induced dissociation than WT Cdc20. APC beads loaded with WT or Cdc20 1-164R were incubated in mitotic extract +/- TAME for 10 min. A fraction of the beads were then treated with Usp2-CD.
Usp2 Catalytic Domain, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/usp2 catalytic domain/product/Enzo Biochem
Average 90 stars, based on 1 article reviews
usp2 catalytic domain - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Biomol GmbH usp2 catalytic domain uw9850
A, HeLa cells were treated±POH1 siRNA for 48 hours before incubation with 10 µg/ml cycloheximide. Cells were lysed and analysed by immunoblotting with ErbB2 29D8 and Ab20 antibodies, which recognize intracellular and extracellular epitopes of ErbB2 respectively, EGFR, and tubulin antibodies. B, quantitation shows that both EGFR (by antibody 1005) and ErbB2 (by antibodies Ab20 and 29D8) are turned over more rapidly in POH1 knock-down cells (data averaged from 3 experiments). C. HeLa cells were treated with four On Target Plus oligos (POH1) or with oligofectamine alone for 72 hours before lysis with hot lysis buffer. A higher molecular weight ErbB2 “smear” was observed in all 4 knock-down samples. D The high molecular weight smear associated with ErbB2 immuno-reactivity is sensitive to treatment with a deubiquitinase <t>(USP2).</t> HeLa cells were treated with POH1 siRNA or oligofectamine for 48 hours before lysis in the presence of NEM. ErbB2 was immunoprecipitated and treated in vitro with USP2 catalytic domain (100 nM, 8 hours, 37°C). Samples were analyzed by immunoblotting with ErbB2 antibodies targeting extracellular (Ab20) and intracellular (29D8) domains. Note that the smear detected with Ab20 is lost upon USP2 treatment whilst detection with the intracellular domain antibody increases. As a control for USP2 DUB-activity, EGFR was immunoprecipitated from EGF-stimulated (5 min) HeLa cells and treated in vitro with USP2 catalytic domain before SDS-PAGE and western blotting with anti-Ubiquitin.
Usp2 Catalytic Domain Uw9850, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/usp2 catalytic domain uw9850/product/Biomol GmbH
Average 90 stars, based on 1 article reviews
usp2 catalytic domain uw9850 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Caltag-Medsystems ltd recombinant human usp2 catalytic domain, cf his tagged
DDI2 Cleaves Ubiquitylated NRF1 Protein In Vitro (A) Western blot analysis of NRF1 protein, isolated via GST-DSK2 chromatography, after treatment with DDI2, RAD23, and <t>USP2,</t> as indicated (4%–15% TGX). The mobility of NRF1 and cleaved NRF1 is shown on the right (see also arrow for cleaved NRF1). Zoomed-in images of lanes 13 and 14 and 19 and 20 are shown below. Note that large amounts of extract were used as input for GST-DSK2 purification, meaning that in relative terms, ~20× “extract equivalents” were loaded in lanes 5–20 compared to lanes 1–4. See also <xref ref-type=Figure S6 A. (B) Reprobing of the membrane from (A), with anti-ubiquitin antibodies. For simplicity, only the relevant lanes 5–9 are shown. (C) Experiment as in (A), but testing DDI2 D→N , as indicated. (D) As in (A) and (B), but testing cleavage of exogenously expressed, Myc-tagged versions of NRF1. N, normal NRF1 sequence. m, mutated sequence. Lower panel, lanes 2 and 6 are shown in the enlargement. The “dot” in lane 6 is not a cleavage band. See also independent experiment in Figure S6 B. " width="250" height="auto" />
Recombinant Human Usp2 Catalytic Domain, Cf His Tagged, supplied by Caltag-Medsystems ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human usp2 catalytic domain, cf his tagged/product/Caltag-Medsystems ltd
Average 90 stars, based on 1 article reviews
recombinant human usp2 catalytic domain, cf his tagged - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

N/A
The Recombinant Human His6 USP2 Catalytic Domain Protein from R D Systems powered by Boston Biochem is derived from E coli The Recombinant Human His6 USP2 Catalytic Domain Protein has been validated for the following
  Buy from Supplier

N/A
The Recombinant Human USP2 Catalytic Domain Protein from R D Systems powered by Boston Biochem is derived from E coli The Recombinant Human USP2 Catalytic Domain Protein has been validated for the following applications Enzyme
  Buy from Supplier

Image Search Results


Cell lysates were prepared from MCF7 cells maintained at 37°C or heat‐shocked at 42°C for 1 h. Where indicated, lysate from heat‐shocked cells was incubated with recombinant USP2 to remove polyubiquitin chains. Equal amounts of cell lysate were assayed for the levels of the indicated proteins by immunoblotting. A quantification of the levels of K48‐linked polyubiquitin is shown in the bar graph (means ± SD, n = 4, number indicates P value calculated with the two‐stage linear step‐up procedure of Benjamini, Krieger, and Yekutieli). Equal amounts of cell lysate described in (A) were fractionated by sucrose density gradient centrifugation, and K48‐linked polyubiquitin was detected by immunoblotting. Quantification of K48‐linked polyubiquitin across the gradients relative to the levels obtained in MCF7 cells maintained at 37°C (means ± SEM, n = 3). Trypsin‐like proteasome activity determined in the same fractions as in (B). Results are shown relative to the proteasome activity obtained in MCF7 cells maintained at 37°C (means ± SEM, n = 3). Source data are available online for this figure.

Journal: The EMBO Journal

Article Title: Dual roles of HSP70 chaperone HSPA1 in quality control of nascent and newly synthesized proteins

doi: 10.15252/embj.2020106183

Figure Lengend Snippet: Cell lysates were prepared from MCF7 cells maintained at 37°C or heat‐shocked at 42°C for 1 h. Where indicated, lysate from heat‐shocked cells was incubated with recombinant USP2 to remove polyubiquitin chains. Equal amounts of cell lysate were assayed for the levels of the indicated proteins by immunoblotting. A quantification of the levels of K48‐linked polyubiquitin is shown in the bar graph (means ± SD, n = 4, number indicates P value calculated with the two‐stage linear step‐up procedure of Benjamini, Krieger, and Yekutieli). Equal amounts of cell lysate described in (A) were fractionated by sucrose density gradient centrifugation, and K48‐linked polyubiquitin was detected by immunoblotting. Quantification of K48‐linked polyubiquitin across the gradients relative to the levels obtained in MCF7 cells maintained at 37°C (means ± SEM, n = 3). Trypsin‐like proteasome activity determined in the same fractions as in (B). Results are shown relative to the proteasome activity obtained in MCF7 cells maintained at 37°C (means ± SEM, n = 3). Source data are available online for this figure.

Article Snippet: To digest K48‐polyubiquitin chains, the lysate was incubated with 7 μg of recombinant human USP2 catalytic domain protein (Boston Biochem, E‐506) for 1 h at 25°C.

Techniques: Incubation, Recombinant, Western Blot, Gradient Centrifugation, Activity Assay

Journal: The EMBO Journal

Article Title: Dual roles of HSP70 chaperone HSPA1 in quality control of nascent and newly synthesized proteins

doi: 10.15252/embj.2020106183

Figure Lengend Snippet:

Article Snippet: To digest K48‐polyubiquitin chains, the lysate was incubated with 7 μg of recombinant human USP2 catalytic domain protein (Boston Biochem, E‐506) for 1 h at 25°C.

Techniques: Recombinant, Sequencing, Magnetic Beads, Staining, Protease Inhibitor, DNA Purification, Bicinchoninic Acid Protein Assay, Modification, Software, Imaging

(a) Schematic illustration of human Cdc20. Asterisks indicate lysine residues. (b) Ubiquitination/dissociation of Cdc20 requires lysines in the N-terminal region. In vitro ubiquitination assays were performed with APC re-loaded with double HA-tagged human WT or Cdc20 mutants as described in . (c) Deubiquitination of ubiquitinated Cdc20 increases its affinity for the APC. Supernatant from an in vitro Cdc20 ubiquitination assay containing ubiquitinated Cdc20 was divided into two aliquots and one aliquot was incubated with the catalytic domain of Usp2 (Usp2-CD). Both aliquots were then re-incubated with a fresh batch of high salt-washed APC to assess the binding of Cdc20. (d) Unmodified Cdc20 outcompetes ubiquitinated Cdc20 for binding to the APC. Ubiquitinated Cdc20 (Ub-Cdc20) was generated as in (c) and mixed with reticulocyte lysate containing unmodified Cdc20 at different ratios. The mixture was then incubated with high salt-washed APC and Cdc20 binding was assessed by Western blot. (e) Cdc20 1-164R is more resistant to TAME-induced dissociation than WT Cdc20. APC beads loaded with WT or Cdc20 1-164R were incubated in mitotic extract +/- TAME for 10 min. A fraction of the beads were then treated with Usp2-CD.

Journal: Nature chemical biology

Article Title: An APC/C inhibitor stabilizes cyclin B1 by prematurely terminating ubiquitination

doi: 10.1038/nchembio.801

Figure Lengend Snippet: (a) Schematic illustration of human Cdc20. Asterisks indicate lysine residues. (b) Ubiquitination/dissociation of Cdc20 requires lysines in the N-terminal region. In vitro ubiquitination assays were performed with APC re-loaded with double HA-tagged human WT or Cdc20 mutants as described in . (c) Deubiquitination of ubiquitinated Cdc20 increases its affinity for the APC. Supernatant from an in vitro Cdc20 ubiquitination assay containing ubiquitinated Cdc20 was divided into two aliquots and one aliquot was incubated with the catalytic domain of Usp2 (Usp2-CD). Both aliquots were then re-incubated with a fresh batch of high salt-washed APC to assess the binding of Cdc20. (d) Unmodified Cdc20 outcompetes ubiquitinated Cdc20 for binding to the APC. Ubiquitinated Cdc20 (Ub-Cdc20) was generated as in (c) and mixed with reticulocyte lysate containing unmodified Cdc20 at different ratios. The mixture was then incubated with high salt-washed APC and Cdc20 binding was assessed by Western blot. (e) Cdc20 1-164R is more resistant to TAME-induced dissociation than WT Cdc20. APC beads loaded with WT or Cdc20 1-164R were incubated in mitotic extract +/- TAME for 10 min. A fraction of the beads were then treated with Usp2-CD.

Article Snippet: The catalytic domain of Usp2 (Usp2-CD, Boston Biochem, E-506, >95% by HPLC) was added to one aliquot at 500 nM and EDTA (1 mM) and DTT (5 mM) were added to both aliquots.

Techniques: Ubiquitin Proteomics, In Vitro, Incubation, Binding Assay, Generated, Western Blot

A, HeLa cells were treated±POH1 siRNA for 48 hours before incubation with 10 µg/ml cycloheximide. Cells were lysed and analysed by immunoblotting with ErbB2 29D8 and Ab20 antibodies, which recognize intracellular and extracellular epitopes of ErbB2 respectively, EGFR, and tubulin antibodies. B, quantitation shows that both EGFR (by antibody 1005) and ErbB2 (by antibodies Ab20 and 29D8) are turned over more rapidly in POH1 knock-down cells (data averaged from 3 experiments). C. HeLa cells were treated with four On Target Plus oligos (POH1) or with oligofectamine alone for 72 hours before lysis with hot lysis buffer. A higher molecular weight ErbB2 “smear” was observed in all 4 knock-down samples. D The high molecular weight smear associated with ErbB2 immuno-reactivity is sensitive to treatment with a deubiquitinase (USP2). HeLa cells were treated with POH1 siRNA or oligofectamine for 48 hours before lysis in the presence of NEM. ErbB2 was immunoprecipitated and treated in vitro with USP2 catalytic domain (100 nM, 8 hours, 37°C). Samples were analyzed by immunoblotting with ErbB2 antibodies targeting extracellular (Ab20) and intracellular (29D8) domains. Note that the smear detected with Ab20 is lost upon USP2 treatment whilst detection with the intracellular domain antibody increases. As a control for USP2 DUB-activity, EGFR was immunoprecipitated from EGF-stimulated (5 min) HeLa cells and treated in vitro with USP2 catalytic domain before SDS-PAGE and western blotting with anti-Ubiquitin.

Journal: PLoS ONE

Article Title: Regulation of ErbB2 Receptor Status by the Proteasomal DUB POH1

doi: 10.1371/journal.pone.0005544

Figure Lengend Snippet: A, HeLa cells were treated±POH1 siRNA for 48 hours before incubation with 10 µg/ml cycloheximide. Cells were lysed and analysed by immunoblotting with ErbB2 29D8 and Ab20 antibodies, which recognize intracellular and extracellular epitopes of ErbB2 respectively, EGFR, and tubulin antibodies. B, quantitation shows that both EGFR (by antibody 1005) and ErbB2 (by antibodies Ab20 and 29D8) are turned over more rapidly in POH1 knock-down cells (data averaged from 3 experiments). C. HeLa cells were treated with four On Target Plus oligos (POH1) or with oligofectamine alone for 72 hours before lysis with hot lysis buffer. A higher molecular weight ErbB2 “smear” was observed in all 4 knock-down samples. D The high molecular weight smear associated with ErbB2 immuno-reactivity is sensitive to treatment with a deubiquitinase (USP2). HeLa cells were treated with POH1 siRNA or oligofectamine for 48 hours before lysis in the presence of NEM. ErbB2 was immunoprecipitated and treated in vitro with USP2 catalytic domain (100 nM, 8 hours, 37°C). Samples were analyzed by immunoblotting with ErbB2 antibodies targeting extracellular (Ab20) and intracellular (29D8) domains. Note that the smear detected with Ab20 is lost upon USP2 treatment whilst detection with the intracellular domain antibody increases. As a control for USP2 DUB-activity, EGFR was immunoprecipitated from EGF-stimulated (5 min) HeLa cells and treated in vitro with USP2 catalytic domain before SDS-PAGE and western blotting with anti-Ubiquitin.

Article Snippet: Samples with or without USP2 catalytic domain (100 nM; BIOMOL, UW9850) were incubated in a thermoshaker for 8 hours (37°C, 1000 rpm).

Techniques: Incubation, Western Blot, Quantitation Assay, Knockdown, Lysis, Molecular Weight, High Molecular Weight, Immunoprecipitation, In Vitro, Control, Activity Assay, SDS Page, Ubiquitin Proteomics

DDI2 Cleaves Ubiquitylated NRF1 Protein In Vitro (A) Western blot analysis of NRF1 protein, isolated via GST-DSK2 chromatography, after treatment with DDI2, RAD23, and USP2, as indicated (4%–15% TGX). The mobility of NRF1 and cleaved NRF1 is shown on the right (see also arrow for cleaved NRF1). Zoomed-in images of lanes 13 and 14 and 19 and 20 are shown below. Note that large amounts of extract were used as input for GST-DSK2 purification, meaning that in relative terms, ~20× “extract equivalents” were loaded in lanes 5–20 compared to lanes 1–4. See also <xref ref-type=Figure S6 A. (B) Reprobing of the membrane from (A), with anti-ubiquitin antibodies. For simplicity, only the relevant lanes 5–9 are shown. (C) Experiment as in (A), but testing DDI2 D→N , as indicated. (D) As in (A) and (B), but testing cleavage of exogenously expressed, Myc-tagged versions of NRF1. N, normal NRF1 sequence. m, mutated sequence. Lower panel, lanes 2 and 6 are shown in the enlargement. The “dot” in lane 6 is not a cleavage band. See also independent experiment in Figure S6 B. " width="100%" height="100%">

Journal: Molecular Cell

Article Title: DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1

doi: 10.1016/j.molcel.2020.05.035

Figure Lengend Snippet: DDI2 Cleaves Ubiquitylated NRF1 Protein In Vitro (A) Western blot analysis of NRF1 protein, isolated via GST-DSK2 chromatography, after treatment with DDI2, RAD23, and USP2, as indicated (4%–15% TGX). The mobility of NRF1 and cleaved NRF1 is shown on the right (see also arrow for cleaved NRF1). Zoomed-in images of lanes 13 and 14 and 19 and 20 are shown below. Note that large amounts of extract were used as input for GST-DSK2 purification, meaning that in relative terms, ~20× “extract equivalents” were loaded in lanes 5–20 compared to lanes 1–4. See also Figure S6 A. (B) Reprobing of the membrane from (A), with anti-ubiquitin antibodies. For simplicity, only the relevant lanes 5–9 are shown. (C) Experiment as in (A), but testing DDI2 D→N , as indicated. (D) As in (A) and (B), but testing cleavage of exogenously expressed, Myc-tagged versions of NRF1. N, normal NRF1 sequence. m, mutated sequence. Lower panel, lanes 2 and 6 are shown in the enlargement. The “dot” in lane 6 is not a cleavage band. See also independent experiment in Figure S6 B.

Article Snippet: Recombinant Human USP2 Catalytic Domain, CF His tagged , CALTAG Medsystems LTD , Cat# AG-40T-0539-C050.

Techniques: In Vitro, Western Blot, Isolation, Chromatography, Purification, Sequencing

DDI2 Fails to Cleave Purified Ubiquitin Chains but Preferentially Binds and Cleaves Slowly Migrating Ubiquitylated Species (A) Coomassie-stained gels of different commercially available ubiquitin chains before and after incubation with DDI2, RAD23, or the catalytic domain of USP2, as indicated. Untreated substrates are indicated by stippled boxes. Note that USP2 cleaves all these chains to mono- or di-ubiquitin. See also lack of detectable mono-/di-ubiquitin in the blot of <xref ref-type=Figure S5 D. (B) Schematic of experiments in (C) and (D). (C) Western blot analysis of ubiquitylated proteins in bound and unbound (supernatant) fractions after incubation with chemically inactivated DDI2 protein (note that two biological replicates of the same experiment are shown; lanes 1 and 2/5 and 6 and lanes 3 and 4/7 and 8). Note the specific depletion of slowly migrating ubiquitylated proteins in lanes 1 and 3 and the enrichment of the same in lanes 5 and 7. (D) As in (C), but ubiquitylated proteins on FLAG-DDI2 D→N beads, incubated with DDI2 or DDI2 D→N (non-FLAG tagged to avoid non-specific “displacement” from the beads), as indicated. Note the disappearance of ubiquitylated proteins from beads after incubation with WT DDI2 (above black stippled line, lane 3) and concomitant release of faster-migrating ubiquitylated proteins into the supernatant (below red stippled line, lane 9). See also ImageJ scanning traces below, with position of stippled lines indicated for reference. Please note that the exposure time of the blot on the right is longer than that on the left; only small amounts DDI2-bound material can be eluted. See also Figure S5 . " width="100%" height="100%">

Journal: Molecular Cell

Article Title: DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1

doi: 10.1016/j.molcel.2020.05.035

Figure Lengend Snippet: DDI2 Fails to Cleave Purified Ubiquitin Chains but Preferentially Binds and Cleaves Slowly Migrating Ubiquitylated Species (A) Coomassie-stained gels of different commercially available ubiquitin chains before and after incubation with DDI2, RAD23, or the catalytic domain of USP2, as indicated. Untreated substrates are indicated by stippled boxes. Note that USP2 cleaves all these chains to mono- or di-ubiquitin. See also lack of detectable mono-/di-ubiquitin in the blot of Figure S5 D. (B) Schematic of experiments in (C) and (D). (C) Western blot analysis of ubiquitylated proteins in bound and unbound (supernatant) fractions after incubation with chemically inactivated DDI2 protein (note that two biological replicates of the same experiment are shown; lanes 1 and 2/5 and 6 and lanes 3 and 4/7 and 8). Note the specific depletion of slowly migrating ubiquitylated proteins in lanes 1 and 3 and the enrichment of the same in lanes 5 and 7. (D) As in (C), but ubiquitylated proteins on FLAG-DDI2 D→N beads, incubated with DDI2 or DDI2 D→N (non-FLAG tagged to avoid non-specific “displacement” from the beads), as indicated. Note the disappearance of ubiquitylated proteins from beads after incubation with WT DDI2 (above black stippled line, lane 3) and concomitant release of faster-migrating ubiquitylated proteins into the supernatant (below red stippled line, lane 9). See also ImageJ scanning traces below, with position of stippled lines indicated for reference. Please note that the exposure time of the blot on the right is longer than that on the left; only small amounts DDI2-bound material can be eluted. See also Figure S5 .

Article Snippet: Recombinant Human USP2 Catalytic Domain, CF His tagged , CALTAG Medsystems LTD , Cat# AG-40T-0539-C050.

Techniques: Purification, Staining, Incubation, Western Blot

Journal: Molecular Cell

Article Title: DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1

doi: 10.1016/j.molcel.2020.05.035

Figure Lengend Snippet:

Article Snippet: Recombinant Human USP2 Catalytic Domain, CF His tagged , CALTAG Medsystems LTD , Cat# AG-40T-0539-C050.

Techniques: Recombinant, Mass Spectrometry, Western Blot, Sequencing, Plasmid Preparation, Software, Transfection